The unintended architect of America’s drug patent drawback

Transcript: Why medication price a lot, 101: Medication monopolies

Word: “An Arm and a Leg” makes use of speech-recognition software program to generate transcripts, which can include errors. Please use the transcript as a software however verify the corresponding audio earlier than quoting the podcast.

Dan: Hey there-

We’re kicking off a brand new sequence right here — We’re calling it An Arm and a Leg 101.

We have spent years of reporting on two enormous questions: Why does well being care price so freaking a lot? And what can we perhaps do about it?

We have been chasing solutions one story, one query at a time.

Now, we’re pulling collectively a few of what we have discovered. Digging just a little deeper, going just a little broader.

Beginning with why so many medication price a lot.

One of many first questions I ever requested — certainly one of our first tales — was: How can insulin be so costly? Wasn’t it found within the early twentieth century? Should not or not it’s a generic drug by now?

, low cost? 

And a part of the reply I bought was: Insulin has been remodeled for the reason that early twentieth century. So much.

A medical researcher named Jing Luo instructed me: At this time’s insulins are a great distance from what we had 100 years in the past.

Jing Luo: They have been actually modified at a molecular stage. It is cool stuff. It is tremendous cool stuff. And , there are a number of Nobel prizes in physiology and drugs which have made this occur.

Dan: And all that super-cool stuff, these superb discoveries, bought patented.

That means: The patent-holders- the pharma firms — bought a monopoly on these superb discoveries.

The pharma firms claimed patents — and monopolies- on a bunch of different issues too. Not all of them superb.

However every new patent can imply one other delay for a generic model coming to market.

Jing Luo: Corporations can stack dozens of patents on high of one another to attempt to thwart generic competitors as a result of they will say, look, we have got three patents on the lively ingredient. We have got patents on the medical makes use of of the lively ingredient. We have got patents on the non-active excipient related to this ingredient. We have got a number of patents on the units, and so that you who’re attempting to enter this area will sue you for patent infringement on all of them.

Dan: A patent ensures you at the least a 20-year monopoly. Medication can usually get an additional 5. 

And these additional patents — secondary patents -can hold you protected LONGER. If you happen to do not file them similtaneously the unique: 

To speak a couple of drug that is within the information proper now. The unique patent on the lively ingredient in Wegovy and Ozempic really expired this yr.. The additional 5 years extends it to the early 2030s. 

However dozens of additional patents — secondary patents, filed later — imply that right here within the U.S., we would not see cheaper generic variations till 2042. Or later.

And as Jing Luo instructed me: This technique is not a secret. It is an business cornerstone. 

Jing Luo: Whenever you pay attention to those like CEOs of pharma firms being interviewed at CNBC, , they’d be like, nicely, what about generic competitors for this product? And so they’ll simply hold saying, no, no, no. We have got this actually sturdy patent portfolio. We are able to face up to any problem. We’re gonna tie this up in courts endlessly and don’t fret about it.We’re gonna proceed this gravy boat for an extended, very long time. That is the best way they reinsure buyers.

Dan: A strong patent portfolio. ?Or what researchers and advocates name a patent thicket.

They are saying high quality issues lower than amount. 

The numbers are wild. 

Based on one examine, the ten best-selling medication for 2021 — medication for most cancers, HIV, arthritis — had been protected by a mixed whole of seven hundred and forty-two patents. With tons of extra “pending.”

When these add-on patents get challenged in court docket, they really get tossed out extra typically than major patents..

However lawsuits price cash. A strong patent portfolio — a patent thicket — means generic firms would have to be able to file a LOT of them.

So, we needed to know: How did all this occur? How did these video games get began?

It seems, there’s one man who can let you know the story from the start, for higher and for worse. Who helped form it. Made hundreds of thousands of {dollars} from it. Noticed its flaws. And has spent a lot of the final 30 years attempting to repair them. Hie’s a lawyer named Al Engelberg, and he is 86 years outdated.

Alfred Engelberg: I inform individuals on a regular basis, I reside in a world, a pharma world the place half the individuals suppose I am lifeless and the opposite half want I used to be. 

Dan: Al Engelberg’s story is the story of generic medication in America. And it is a wild journey. 

That is An Arm and a Leg — a present about why well being care prices so freaking a lot, and what we are able to perhaps do about it. I am Dan Weissmann. I am a reporter, and I like a problem. So the job we have chosen right here is to take probably the most enraging, terrifying, miserable components of American life, and produce you one thing entertaining, empowering, and helpful.

?Al Engelberg’s dad and mom fled Nazi Germany within the late Nineteen Thirties.

He was born right here, lower than a yr after they arrived. That they had nothing.

And this is the place they made their new life. 

Retro information reel: We’re flying over a well known japanese metropolis. That’s outstanding as a result of manufacturing is nearly non-existent. A metropolis whose precept enterprise is the leisure of hundreds of thousands. Atlantic metropolis, typically referred to as the holiday capital of the nation

Dan: Al likes to say he discovered most of what he is aware of about training regulation on the Atlantic Metropolis boardwalk, by the point he was 16. 

Alfred Engelberg: We grew up very, very quick there. I began working once I was about 9 or 10 and, and there have been a lot of alternatives on the boardwalk. 

Dan: His first “job” was crawling round beneath the boardwalk, in search of unfastened change.

Alfred Engelberg: However I went on to work at hotdog stands and at an unlawful bingo recreation for the native mob.

Dan: And in each job, Atlantic Metropolis drove house its main lesson: Dishonest — hustling — is one thing you’ve got gotta anticipate. 

At this unlawful bingo parlor, Al’s job was strolling between tables, doling out bingo playing cards for a dime apiece. The bosses employed faculty youngsters to stroll behind youngsters like Al, to maintain him sincere.

Alfred Engelberg: I imply, these guys are operating an unlawful recreation, however they nonetheless must depend, they usually nonetheless inherently do not belief anyone. 

Dan: Which was appropriate. Al says the faculty youngsters had their very own hustle: They’d have him put aside a greenback or two earlier than handing over his dimes — cut up that greenback with him fifty-fifty — and inform the bosses Al’s depend was wonderful.

Alfred Engelberg: And everyone figuring out that the counts had been wildly inaccurate anyway ‘trigger the little outdated girls had been, had been stealing playing cards. Everyone within the room had their very own factor going, , from the shoppers on.

Dan: After Al made it out of Atlantic Metropolis, his distinctive on-the-job schooling continued. He studied chemical engineering at Drexel, then took a job as a patent examiner whereas going to regulation faculty at night time.

And at that job, he discovered: The patent system was ripe for hustling.

Partly as a result of most of his colleagues weren’t essentially giving the job their all. 

Like him, most patent examiners had been working their method by way of regulation faculty. And so they had been sneaking time to check on the job.

Alfred Engelberg: We used to have the ability to lower our notes down in order that they slot in these file drawers with the patents. And we might be studying your notes and in case your boss got here by, you’ll simply drop a patent on high of the notes.

Dan: You would say it was Atlantic Metropolis yet again. Everyone within the job is sneaking one thing for themselves — on this case, time.

And Al Engelberg may see that, even when his colleagues gave it their all, they had been too inexperienced to do their job nicely. 

A patent examiner’s job — deciding whether or not a proposed invention deserves a monopoly (which at the moment was 17 years) — means deciding whether or not the concept for that invention can be apparent to “an individual of strange talent in that subject.”

Alfred Engelberg: And a lot of the examiners had by no means labored in that subject and had completely no concept. And that is the large leagues. You are granting any person a monopoly for 17 years, and it appeared ridiculous on its face.

Dan: Al lower his personal path on the patent workplace. He’d labored his method by way of engineering faculty, in manufacturing vegetation, he noticed what individuals of strange talent in that subject remedy issues day by day. So he specialised in analyzing patents he really knew one thing about.

That bought him promoted, then it bought him recruited by a company lawyer.. After the corporate paid his method by way of the remainder of regulation faculty, he jumped to the Justice Division. 

He was ambitious- he needed expertise junior legal professionals do not normally get — like attempting circumstances of his personal.

After a couple of years doing simply that, he took a job with a small regulation agency in New York Metropolis in 1968.

Alfred Engelberg: I got here to New York to non-public follow on the age of 30 and I used to be able to go. I imply, I used to be able to, to tear the world aside and I did.

Dan: Patents had been nonetheless a specialty. Then, in 1973, he will get a name that results in his first generic drug case.

Generic medication weren’t a scorching market on the time.

Alfred Engelberg: ?The generic drug business in Nineteen Seventies was primarily, a half a dozen, privately owned household companies, largely within the metropolitan New York space. And a lot of the medication that they had been promoting had been medication that had been authorized earlier than 1962. 

Dan: Yeah. 1962 is when the FDA made it tougher to get a brand new drug authorized — you needed to undergo lengthy medical trials to indicate that your drug was secure and efficient. 

Even when your drug was a generic model of an present drug. These little firms did not have the capital to run these trials, in order that they had been caught promoting these outdated medication.

Not a lot of a enterprise. Perhaps 20 % of prescriptions had been for generic medication.

So when Al Engelberg bought a name for his first generic drug case, that was the context. And the case itself didn’t sound promising. For one factor:

Alfred Engelberg: The decision wasn’t even from the consumer. It was from a financial institution. The consumer was bankrupt. 

Dan: The consumer was bankrupt. This bankrupt consumer, Premo Prescribed drugs, was getting sued for patent infringement. The financial institution was prepared to place up ten thousand {dollars} for a protection. Nowhere close to sufficient to truly attempt a case. Oh, and…

Alfred Engelberg: From what they instructed me, the data they gave me, we did not have an excellent protection.

Dan: However Al Engelberg noticed a gap. He may see that his opponents have weaknesses too.

Alfred Engelberg: The patent house owners had been in a really unusual place. In the event that they gained, they bought nothing as a result of we had been already bankrupt. Two, they had been gonna need to spend the authorized charges to win.

Dan: Win towards a younger lawyer named Al Engelberg who already had a rep as a tricky opponent. So they might lose.

Alfred Engelberg: And in the event that they misplaced, they might lose hundreds of thousands and hundreds of thousands of {dollars} in enterprise as a result of there would not be a patent. And so they’d have competitors from generic medication.

Dan: And in the meantime, Al Engelberg can also be sizing up the choose. He is aware of the man does not love patents.

So Al reveals as much as the primary convention and he bluffs. 

Alfred Engelberg: I mentioned to the choose, oh, your Honor, , it is one other a type of patents. They’re all invalid. And I mentioned, we do not want very a lot discovery. We’re, we’ll be able to go to trial in a couple of months. Simply set a trial date.

Dan: The opposite aspect walks out beside themselves.

And inside a few weeks they name Al to say: Hey, how about this? You guys simply acknowledge our patent is OK, and we’ll provide the cash we’d’ve spent litigating. Name it 400,000 bucks?

Alfred Engelberg: I referred to as the consumer and mentioned, how’s $400,000? He mentioned, are you kidding?

Dan: They did not simply get out of hassle — they bought out of chapter, with $400,000 of their pockets. As a result of Al Engelberg knew methods to measurement up a scenario. 

Alfred Engelberg: You do not study that in regulation faculty. That is not what they train.

Dan: Phrase will get round about that case, and fairly quickly everyone within the generic drug world is asking him.

It is a small world, however by the tip of the Nineteen Seventies, there could also be room for it to begin getting greater. 

Individuals are beginning to discover: Medication are costly. Perhaps there ought to be extra low cost generics. 

Some generic drug firms type an affiliation and begin lobbying: Make it simpler to get generic medication to market with out having to undergo all these trials.

The brand-name drugmakers push again: They are saying it takes so lengthy to run the trials and get their medication authorized, they do not get sufficient time to earn money earlier than these patents expire.

In 1983, Democratic Consultant Henry Waxman steps in to dealer a compromise, with Republican Senator Orrin Hatch.

And Mr. Engelberg goes to Washington. To run technique for the generic drugmakers. 

Alfred Engelberg: In lots of methods , that is the place my Atlantic Metropolis coaching actually helped me on the finish of the day

Dan: There have been lots of people, with lots of pursuits. Numerous angles. ?He begins commuting from New York to Washington DC a pair instances per week — for months and months, greater than a yr.

And Al Engelberg says: This time, it wasn’t nearly profitable a case.

Alfred Engelberg: I used to be behind a cab the best way I bear in mind, with the senior accomplice of the regulation agency. And he says to me, why are you breaking your ass going to Washington two or thrice? Why do not you ship an affiliate? , it is identical to, it is simply one other case. And I mentioned. I mentioned, are you kidding? I mentioned, , what number of legal professionals ever get to do what I am doing proper now? To be on the desk influencing what could also be a serious regulation that is gonna have main penalties is, is like one thing I by no means thought my complete life I might be doing.

Dan: A child from Atlantic Metropolis was precisely the appropriate particular person to attempt to steadiness all of the angles, negotiate a compromise. It took greater than a yr. It nearly did not occur. However then it did. Congress handed the invoice, and President Ronald Reagan bought in entrance of cameras to signal it.

Ronald Reagan: Let me flip my consideration to the actual purpose we’re right here this afternoon, signing into regulation the Drug Worth Competitors and Patent Time period Restoration Act of 1984. 

Dan: higher often called Hatch-Waxman.

Hatch Waxman had three fundamental elements:

One: Model drugmakers bought a couple of additional years on their patents.

Two: Generic drugmakers bought a pathway to get FDA approval.

And three -The brand new regulation laid out guidelines for a generic drugmaker after they needed to CHALLENGE an present patent. 

Negotiating that third half was the half the place Al Engelberg’s schooling on the Atlantic Metropolis boardwalk, and the U.S. patent workplace, and the generic drug business got here collectively: The outcome would make him hundreds of thousands and hundreds of thousands of {dollars} — and blow an enormous gap into the grand cut price he had labored so arduous to result in.

That is coming proper up.

This episode of An arm and a Leg is produced in partnership with KFF Well being Information. That is a nonprofit newsroom masking well being points in America. The parents at KFF Well being Information are superb journalists — their work wins every kind of awards, yearly. We’re honored to work with them.

So. The brand-name drug makers and the generic drug makers struck a deal. That deal was good for them. Each side bought one thing large out of it. The general public was imagined to get one thing out of it too.

And, to be truthful, we did: Bear in mind, again then, perhaps one out of 5 prescriptions was for a generic drug. Now it is 9 out of ten.

However we pay greater than ever for medication. Largely for branded, patent-protected medication. And the largest, most-important, most worthwhile medication get locked behind patent thickets.

How did that occur? 

Nicely, to grasp that, it helps to know what Al Engelberg bought out of the entire cut price.

Al had been there on the bargaining desk, on behalf of the generics. 

At some point, throughout these negotiations, he was within the workplace with Henry Waxman’s lead counsel, a man named Invoice Corr, when Corr bought a name from somebody on the opposite aspect.

Corr begins pointing on the cellphone, pointing to Al — indicating: This man is speaking about you.

When Corr will get off the cellphone he says: That man’s undecided about this deal the place unhealthy patents may very well be challenged. He is suspicious about the place you may take this. Like, are you simply gonna arrange a bounty-hunting operation, to get patents declared invalid?

And Corr mentioned, Al, would you try this? 

Alfred Engelberg: And I mentioned, , Invoice, till this second, I’ve by no means given it any thought, but it surely’s a hell of a good suggestion. Perhaps I will take a look at it. 

Dan: And he did. Beginning nearly as quickly as Hatch-Waxman turned regulation.

Alfred Engelberg: And we sat within the rose backyard, September twenty third, 1984, watched Reagan signal the invoice. And in December of that yr, I sat down at my kitchen desk with a yellow pad and I laid out a method.

Dan: If you happen to had been gonna arrange a bounty-hunting operation, how would you do it?

Al Engelberg knew lots of patents had been rubbish. Knew it from his time within the patent workplace, knew it from training regulation. And he knew how a lot cash a profitable patent problem may very well be value.

The way in which Hatch-Waxman labored: If a generic drug firm challenged a patent and gained, they might get six months earlier than any OTHER generic drugmakers may get a crack on the market.

So their solely competitors can be the model. If a tablet price two cents to make, and the model was promoting for a greenback a tablet — that is 98 cents of revenue for each tablet.

You are the one competitor? You would cost 75 cents a tablet and get 73 cents of revenue. On successful drug, you possibly can make hundreds of thousands and hundreds of thousands — simply in these six months. 

Al’s concept was this: Companion up with a generic drugmaker. Go discover cases- medication with weak patents. Win ’em. 

And cut up these hundreds of thousands in potential earnings fifty-fifty. 

Al pitched a generic drugmaker — they had been able to go — and introduced the deal to his regulation agency. .

Alfred Engelberg: Because it turned out, my companions weren’t fascinated by having me do that. They tried to speak me out of it.

Dan: However they could not. So he left. Went out on his personal. All on his personal.

Alfred Engelberg: I by no means employed a single soul, not even a secretary. And I could not sort. I nonetheless cannot sort.

Dan: However he hunted and pecked his method by way of transient after transient. He purchased an early moveable laptop — it weighed thirty kilos — and lugged it round behind his automobile. For ten years.

Alfred Engelberg: It was silly. I nearly killed myself. However, it labored out okay.

Dan: Yeah. Seems Al was actually good at discovering the issues with drug patents.

In certainly one of his first circumstances, Al Engelberg personally made greater than 70 million {dollars}. Others settled: Just a few million right here, a couple of million there- it provides up.

After which…

Alfred Engelberg: It bought to be the mid nineties, and I used to be engaged on a case referred to as Buspar. 

Dan: The Buspar case ended up an enormous winner for Al Engelberg and his generic drug companions. 

Nevertheless it had penalties that went method past a single case. And led to large losses for the general public.. Here is the way it went. 

Alfred Engelberg: Buspar was an anti-anxiety drug. And by all accounts not an excellent one.

Dan: However Bristol Meyers Squibb invested in large promoting and advertising campaigns.

Speaker 5: I really feel anxious. I can not focus. 

Speaker 6: I am so irritable. If you happen to. You undergo from extreme fear. It could really feel like a mountain of hysteria. 

Speaker 5: I will by no means get all of it achieved. I am overwhelmed. 

Speaker 6: However a prescription treatment referred to as buspar might help.

Dan: And all that advertising did its job. By the mid-Nineties, Buspar was making greater than 200 million {dollars} a yr for Bristol.

Alfred Engelberg: The one drawback for them was that the drug was not new. 

Dan: The lively ingredient was well-known in medical literature as a tranquilizer. No person had bothered to promote it.

So Bristol Myers Squibb filed a patent on it, claiming it had found a brand new use for this well-known tranquilizer: Treating nervousness.

Al Engelberg says when he learn the patent utility, he may barely imagine it: What do tranquilizers do if not… deal with nervousness?

It is like saying: There’s these things referred to as sugar. We’re gonna take out a patent on utilizing it as a sweetener.

This seemed like a case for a man from Atlantic Metropolis. 

Alfred Engelberg: I did one thing that legal professionals do not. That is simply the best way I used to be constructed. 

I filed a movement with the court docket and principally mentioned, we do not want any proof.

You simply need to learn the patent. If you happen to imagine it is true, the patent’s invalid. Simply, , all you want is a dictionary principally.

Dan: Al says Bristol was wanting to settle. 

Alfred Engelberg: We get right into a settlement dialogue and we hold saying, no, no, no, no.

Dan: Al’s companions had achieved the maths: They figured they stood to make 100 million {dollars} or extra as soon as they gained. So when the opposite aspect supplied 25 million, no was the straightforward reply.

Alfred Engelberg: We mentioned, why are we gonna take this? , it is loopy. There is a reward right here we all know what it’s. We’re gonna get it will definitely.

Dan: Al sits down with a lawyer from the opposite aspect, a man he is aware of, explains how he sees the maths.

And shortly the opposite aspect comes by way of with a a lot greater provide: 72 million {dollars} – nearly thrice as a lot. 

Alfred Engelberg: And I am sitting there like, what are you loopy? However then give it some thought from their perspective. 

Dan: Paying 72 million {dollars} is nothing, in comparison with what Bristol stands to achieve if this lawsuit goes away. 

With their monopoly, Bristol Meyer Squibb is making greater than 200 million {dollars} a yr on Buspar. And until any person else strains as much as do what Al Engelberg had achieved, anticipate to maintain that monopoly for years.

Charging no matter they need. Two {dollars} a tablet, three {dollars} a tablet. Which Al Engelberg says is strictly what occurred.

The truth is, they stored that monopoly for like 5 years. 

Alfred Engelberg: Because it turned out, no person got here behind us. And so, that they had that monopoly till 2000. In order that they bought 5 years of two billion, in gross earnings. 

Dan: They made out.

Alfred Engelberg: For the price of $75 million. And , the general public bought screwed ‘trigger they’re persevering with to pay, , $2 a tablet or $3 a tablet for a drug that finally finally ends up being accessible for 20 or 30 cents. Um, in order that’s, that is the way it works.

Dan: That is the way it works. The branded firm and the generic firm each make out nice. Cheaper generic variations of a drug get delayed. 

That incredible payday for Al Engelberg and his companions on the generic drug firm became a mannequin a template for the sort of deal that each generic drug firm would need in on.

It bought a nickname: Pay for delay.

Alfred Engelberg: That unfold by way of the business like wildfire, these numbers, , you do not make these numbers half a cent at a time on, on drugs,

Dan: Lawsuits had been far more worthwhile.

However Al Engelberg wasn’t submitting them.

A yr or so after the Buspar case settled, sparking the Pay for Delay gold rush, he retired. He had loads of cash and nothing to show.

And in retirement, he began evaluating what he’d achieved, for higher and for worse.

For higher, generic medication had greater than doubled their share of the market since Hatch-Waxman took impact.

For worse, he may see two locations the place — regardless of all of his Atlantic Metropolis coaching — he had missed a few angles in negotiating Hatch-Waxman. 

One was: this complete pay-for-delay scheme. Turned out, in balancing incentives for manufacturers and generic makers, he’d left open this perverse incentive that left the general public out. 

And the second was a loophole that Hatch-Waxman had left open.: 

It created a course of the place gamers like Al and his generic companions may problem patents on medication like Buspar, that they thought did not deserve protected monopolies. It eliminated some friction for these assaults. 

The drug firms developed a method so as to add extra friction: stacking additional patents — secondary patents — on each drug.

Creating patent thickets.

Even when a secondary patent is trivial — and plenty of them do get tossed out — difficult it means a court docket combat. And that prices cash.

Alfred Engelberg: It triggered the large drug firms to only get increasingly patents. As a result of why not? , there was nothing standing in the best way.

Dan: I imply, no person is aware of higher than Al Engelberg: Patent examiners do not precisely stand in the best way. 

And people patent thickets and pay for delay, they feed on one another. 

Alfred Engelberg: The economics of the enterprise, triggered these sorts of settlements to achieve epic proportions. So the generic firms would, problem these secondary patents and, the drug firms would pay them off.

Dan: In 1999 he revealed an article in a scholarly journal arguing that Hatch-Waxman wanted a reboot. Even the six-month head begin for a profitable problem may in all probability go. 

And ever since — for greater than twenty-five years — he is poured hundreds of thousands of {dollars} into efforts to tighten the principles. Funding analysis. A public-information marketing campaign from Shopper Reviews. Even a middle for IP regulation at his alma mater, NYU.

It hasn’t at all times gone his method. 

Pay for delay has gotten a lot greater since Al Engelberg wrote his first article calling for reform: He wrote in 1999 that about two dozen patent challenges had been filed.

Now he estimates that quantity at twelve thousand.

Alfred Engelberg: I can not let you know what number of tens of billions of {dollars} in authorized charges that’s. It is one of many quickest rising and and steadiest industries for large regulation.

Dan: A Hatch-Waxman litigation discussion board on LinkedIn has greater than fourteen thousand members.

And Hatch-Waxman does not cowl lots of right now’s the top-selling drugs- the largest moneymakers. They belong to a category referred to as “biologics.”

That features famously-expensive rheumatoid arthritis medication like Humira and Enbrel — and insulin. 

Biologics weren’t a class forty years in the past when Hatch-Waxman bought negotiated. Congress handed a brand new regulation to cope with them in 2010 — ?the Biologics Worth Competitors and Innovation Act.

Al Engelberg just isn’t a fan of that regulation.

Alfred Engelberg: No matter errors had been made in Hatch Waxman, they had been multiplied by 10 and intentionally within the biologics regulation

Dan: He says the all however encourages patent thickets. And does not present a pathway to problem them.

He says it reminds him of a few of his early days training regulation.

Alfred Engelberg: Again within the seventies, we used to have small startup shoppers within the laptop subject, and they might get letters from IBM. It says, we’re prepared to tell you that you could be be infringing a number of of the next patents. And there was a ten web page checklist of patents hooked up. And the startup would come to us and say, , what ought to we do? And we might say, discover one other line of labor, , what are you gonna do?

Dan: However he has not given up. In 2025, he revealed a ebook: Breaking the Medication Monopolies.

It tells the story of his profession — and lays out his prescriptions for fixing the issue.

He does not JUST deal with plugging the holes in Hatch-Waxman and the biologics regulation.

Alfred Engelberg: , we do not really want a generic drug business. We’d like generic drug pricing. 

Dan: He is bought proposals for an elevated authorities position in negotiating and regulating costs — and greater than that.

He argues {that a} 1980 regulation permits the federal government to commisssion generic variations of medicine that had been developed utilizing public analysis {dollars}.

He additionally says the FDA guidelines that defend secondary patents on medication — that enable patent thicketing — are primarily based on a totally flawed interpretation of Hatch-Waxman.

And tells us he is working up a problem, with assist from AI instruments like Claude. 

He is 86 years outdated. And he does not appear inclined to cease.

Alfred Engelberg: It so modified my life and I did so nicely by it, I believed, how can I not tackle this drawback? Who’s gonna do it if I do not do it?

Dan: He is bought the time. Cash’s no object. And he is aware of the territory in addition to anyone. He helped create it. 

Alfred Engelberg: So it is, it is my obligation actually. It is that form of Jewish guilt. What can I let you know? I am paying again for the bingo recreation.

Dan: So we have gone again greater than fifty years on the query: Why aren’t there extra generic medication? We have discovered why we have got those now we have, and what stands in the best way of getting extra.

And that’s simply in time. As a result of this spring the U.S. Supreme Courtroom will hear arguments in a case that might limit the generic drug pipeline even additional. It may have main implications.

And understanding what they’re requires the entire 101 we have lined right here. We’ll have that story for you in a couple of weeks. Til then, maintain your self. 

This episode of An Arm and a Leg was produced by Emily Pisacreta, with assist from Dan Weissmann— and edited by Ellen Weiss. 

Adam Raymonda is our audio wizard.

Our music is by Dave Weiner and Blue Dot Periods. 

Claire Davenport is our engagement producer.

Sarah Ballema is our Operations Supervisor. Bea Bosco is our consulting director of operations. 

This sequence — An Arm and a Leg 101 — is made doable partly by assist from Arnold Ventures. 

An Arm and a Leg is produced in partnership with KFF Well being Information. That is a nationwide newsroom producing in-depth journalism about well being points in America and a core program at KFF, an impartial supply of well being coverage analysis, polling, and journalism.

 Zach Dyer is senior audio producer at KFF Well being Information. He is editorial liaison to this present.

An Arm and a Leg is distributed by KUOW, Seattle’s NPR information station.

And because of the Institute for Nonprofit Information for serving as our fiscal sponsor.

They permit us to simply accept tax-exempt donations. You’ll be able to study extra about INN at INN.org.

Lastly, thanks to everyone who helps this present financially.

You’ll be able to take part any time at arm and a leg present, dot com, slash: assist.